GlassScriptPhysician profile
Peter J Montesano
NPI 1093845281
$1,758.32
in general payments reported to CMS, 2019-2025
25 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $167 · 2021: $180 · 2022: $328 · 2023: $219 · 2024: $295 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699 · Consulting Fee: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.11 |
| Consulting Fee | $105.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $227.86 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $152.76 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $139.61 | 2022-2025 | Repatha, Otezla |
| Pfizer INC. | $133.77 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.15 | 2021-2025 | Eliquis |
| Adma Biomanufacturing LLC | $105.01 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.27 | 2022 | |
| Shire North American Group INC | $87.35 | 2019 | |
| Genentech USA, INC. | $62.80 | 2023 | Xolair |
| Novo Nordisk INC | $51.87 | 2020-2022 | |
| Eisai INC. | $35.46 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.93 | 2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $20.42 | 2025 | Rezdiffra |
| Viiv Healthcare Company | $18.54 | 2025 | Apretude |
| Biohaven Pharmaceutical Holding Company LTD. | $17.95 | 2022 | |
| Viatris Specialty LLC | $17.41 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $16.88 | 2019 | |
| Lilly USA, LLC | $16.79 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.40 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.03 | 2022 | |
| Alkermes, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Montesano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.